CN

Adverse reaction report

MENU

B1-pc-banner.jpg B1-ph-banner-ny.jpg
HOME
ABOUT SINOT
Overview

About SinoT

Company Profile
Company Culture
Company History

Company Profile

Sinotherapeutics was founded in August 2012. It is a specialty pharma focus on the R&D, registration, manufacture and commercialization of complex generic products as well as innovative formulation products (505B2). The company aims to achieve commercialize its product globally, and to provide cost-effective high-quality products to international markets. The company has launched its product in multiple markets around the world, including metabolic, oncoly and CNS products.   The company has its headquarter and R&D center located in the high-tech park in Pudong Zhangjiang district, Shanghai, China. The R&D center is well setup for formulation preparations, GMP analytical labs, and GMP pilot plants.The company also has a wholly owned commercial oral solid dosage form manufacture facilities, and high-potency formulation suits,  both are located in Haimen City Jiangsu Provice, and have been audited and qualified multipletimes by US FDA and Chinese NMPA.

The company's business also involves a small scale of the R&D, production and sales of high-end nutraceutical, nutritional products and dietary supplements.

55000㎡

Sinotherapeutics has a manufacturing facilities for multiple oral dosage forms with a size of about 55 thousand square meters.

10+times

The manufacture facility has been successfully passed multiple times the audits by FDA and NMPA.

20+years

Management Team has many years of industrial experience in product lifecycle management and project management.

b1_01.jpg
b1_ic1.svg

Better Medicines
Better Lives

b1_02.jpg
b1_ic2.svg

Honesty and Dedication,
Shared Efforts for
Shared Future

B1-04.jpg
b1_ic3.svg

Be Great In
Contemplation, Articulation
Execution and Realization

Mission

Vision

b1_ic4_1.svg

Mission

To improve patient’s health and quality of life with pharmaceutical products that are of high quality and cost-effective, through technological optimization and innovation.

b1_ic5_1.svg

Vision

To be a leader in the specialty pharmaceutical industry in China and the rest of the world, serving the public and society with pharmaceutical products that are of high quality and cost-effectiveness.

Company History

2021
  • 01Posaconazole Delayed-Released Tablets was approved by Chinese NMPA and launched in the Chinese market, and by Australia and launched in the Australia market.
  • 02Take an equity stake in Chengdu D-innovation Pharmaceutical Co., Ltd, a high-tech company integrating R&D, manufacturing and sale of pharmaceutical intermediates and APIs.
  • 01Company competed formalization of SinoT equity share holding and assignments, which enable SinoT to become an equity company with multiple registered shareholders.
  • 01Propafenone Extended Release Tablets was approved by FDA and launched in US market.
  • 02Posaconazole Delayed-Released Tablets was approved by FDA and launched in the US market as the first generic.
  • 03Haimen Manufacturing facility received and passed on-site audit by FDA for the third time.
  • 04Company successfully applied for and received the Shanghai Enterprise Patent Pilot Unit---a recognition of company’s heavy engagement in patent applications.
  • 01Company completed series-A fund rasing of ￥200 million RMB.
  • 02Quetiapine Fumarate Extended Release Tablets was approved by FDA and launched in US marketed.
  • 03Haimen Manufacturing facility received and passed the on-site audit by FDA for the second time.
  • 01Sinotherapeutics Inc. was recognized as one of the high-tech enterprises in China;
  • 02Bupropion Extended-Release Tablets was approved by FDA and launched in the US marketed;
  • 03Metformin Hydrochloride Extended-Release Tablets was approved by FDA and launched in US marketed.
  • 01Shanghai R&D center and Haimen manufacturing facility received and passed the on-site audits conducted by FDA for the first time.
  • 01Haimen Pharma Inc Manufacturing facility received a certification of GMP issued by NMPA.
  • 01Acquired Haimen Pharma Inc. as the wholly owned manufacturing facility of oral solid dosage forms.
  • 02Sinonutraceutical co.,Ltd. founded, dedicated to the R&D, manufacturing and distribution of high-end nutraceutical/nutritional and dietary supplement products.
  • 01Sinotherapeutics Inc. founded in Aug. 2012
  • 0
1 / {count($years)}
  • SCROLL

Shanghai Head Office

86 21-6881-9009

99 Haike Road, Bldg. 3, 1st Flr., Pudong District Shanghai 201210, P.R. China

Manufacturing Site in Jiangsu

86 513-8122-1988

No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province

CRO/CDMO Service
News
Products
Lauched Drug
Pending Approvals
ABOUT SINOT
Overview
R&D and Manufacturing
Contact Us
Career
Talent Recruitment
Talent Development and Motivations
Staff activities
Links
Haimen Pharm
Vastpro
D-innovation
qrcode.jpg

Focus on us

Copyright © 2014-2022 SINOTHERAPEUTICS.COM ICP：13048014-1   Powered by Yongsy

Privacy Legal